These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29363049)

  • 21. The Pharmacodynamics of Prolonged Infusion β-Lactams for the Treatment of Pseudomonas aeruginosa Infections: A Systematic Review.
    Thabit AK; Hobbs ALV; Guzman OE; Shea KM
    Clin Ther; 2019 Nov; 41(11):2397-2415.e8. PubMed ID: 31679822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolonged β-lactam infusion for Gram-negative Infections.
    Tamma PD; Jenh AM; Milstone AM
    Pediatr Infect Dis J; 2011 Apr; 30(4):336-7. PubMed ID: 21407037
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis.
    Gatti M; Cojutti PG; Pea F
    Crit Care; 2024 Apr; 28(1):123. PubMed ID: 38627763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria.
    Pintado V; San Miguel LG; Grill F; Mejía B; Cobo J; Fortún J; Martín-Dávila P; Moreno S
    J Infect; 2008 Mar; 56(3):185-90. PubMed ID: 18280570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
    Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
    Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minor fluctuations in renal function may alter therapeutic drug concentrations substantially during high-dose, continuous-infusion beta-lactam therapy for multi-drug-resistant Gram-negative bacilli.
    Afaneh CI; Ho VP; McWhorter P; Nicolau DP; Barie PS
    Surg Infect (Larchmt); 2012 Dec; 13(6):415-7. PubMed ID: 23268616
    [No Abstract]   [Full Text] [Related]  

  • 31. Resistance to empirical β-lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study.
    Chumbita M; Puerta-Alcalde P; Yáñez L; Cuesta MA; Chinea A; Español Morales I; Fernández Abellán P; Gudiol C; Guerreiro M; González-Sierra P; Rojas R; Sánchez Pina JM; Sánchez Vadillo I; Varela R; Vázquez L; Lopera C; Monzó P; Garcia-Vidal C
    J Antimicrob Chemother; 2022 Jun; 77(7):2017-2023. PubMed ID: 35466357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ciprofloxacin use and susceptibility of Gram-negative organisms to quinolone and non-quinolone antibiotics.
    Troughton JA; Millar G; Smyth ET; Doherty L; McMullan R
    J Antimicrob Chemother; 2011 Sep; 66(9):2152-8. PubMed ID: 21700624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
    Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
    Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
    Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
    Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.
    Dinubile MJ; Friedland I; Chan CY; Motyl MR; Giezek H; Shivaprakash M; Weinstein RA; Quinn JP
    Eur J Clin Microbiol Infect Dis; 2005 Jul; 24(7):443-9. PubMed ID: 15990986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamics of cefepime in patients with Gram-negative infections.
    Tam VH; McKinnon PS; Akins RL; Rybak MJ; Drusano GL
    J Antimicrob Chemother; 2002 Sep; 50(3):425-8. PubMed ID: 12205070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study.
    Carrié C; Petit L; d'Houdain N; Sauvage N; Cottenceau V; Lafitte M; Foumenteze C; Hisz Q; Menu D; Legeron R; Breilh D; Sztark F
    Int J Antimicrob Agents; 2018 Mar; 51(3):443-449. PubMed ID: 29180280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new beta-lactamases.
    Jacoby GA; Munoz-Price LS
    N Engl J Med; 2005 Jan; 352(4):380-91. PubMed ID: 15673804
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.